Research Evidence
Phase I Clinical Trial (Life Sciences, 1996): Dorr et al. confirmed that MT-II produced significant skin pigmentation increases in humans with minimal UV exposure, establishing dose-dependent tanning effects and a basic safety profile in a pilot human study.
Erectile Dysfunction Research (Journal of Urology, 1998): Wessells et al. demonstrated that MT-II produced erections in men with psychogenic erectile dysfunction in a double-blind, placebo-controlled crossover study. This research supported the central mechanism of action and directly contributed to the development of bremelanotide (PT-141), which was later FDA-approved for hypoactive sexual desire disorder in women.
Melanocortin Receptor Pharmacology: Studies by Hruby et al. and others elucidated MT-II's receptor binding profile and downstream effects across physiological systems, informing the understanding of both its therapeutic potential and side effect profile.
Animal Studies: Preclinical research demonstrated appetite-suppressing effects of melanocortin receptor agonists, including MT-II. Human body composition data on MT-II specifically remains limited, and animal findings have not been replicated in controlled human trials.
Review Evidence: A 2019 review in Dermatology Online Journal by Brennan et al. assessed the available evidence for MT-II efficacy and safety, noting the gap between preclinical promise and the absence of phase II/III clinical trial data for any indication.